← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Other immunosuppressants
monomethyl fumarate
L04AX11
Forms & Strengths
- Delayed-release capsules: 95 mg
- Delayed-release capsules: 190 mg
Adult Dosing
- Initial: 95 mg orally twice daily for 7 days
- Maintenance: 190 mg orally twice daily
Pediatric Dosing
- Safety and efficacy in pediatric patients not established
Indications
- Treatment of relapsing forms of multiple sclerosis in adults
Mechanism of Action
- Activates the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway
- Exerts anti-inflammatory and cytoprotective effects against oxidative stress
Contraindications
- Known hypersensitivity to monomethyl fumarate, dimethyl fumarate, or excipients
- Patients with severe gastrointestinal disease
- Moderate to severe renal impairment
Adverse Reactions
- Flushing
- Abdominal pain
- Diarrhea
- Nausea
- Lymphopenia
- Proteinuria
Drug Interactions
- Avoid concurrent use with other fumaric acid derivatives
- Immunosuppressive therapies may increase the risk of serious infections
- Nephrotoxic drugs may increase the risk of renal adverse effects
Curated Content: Needs Vetting Before Put to Clinical Use